Juan Carlos Lopez to assist business development in North America
LifeArc has appointed Juan Carlos Lopez, founder of Haystack Science, to assist their business development activity in…
LifeArc’s Head of Ventures, Clare Terlouw speaks with @FT Global Pharma Correspondent @hannahkuchler discussing RQ… https://t.co/fqrxEXr3Xf
Partnership with Metrion Biosciences to support LifeArc’s neuroscience small molecule drug discovery programme
Metrion to provide in-depth ion channel target class knowledge and assay support.
LifeArc becomes technology transfer partner to London School of Hygiene & Tropical Medicine
LifeArc has signed an agreement with the London School of Hygiene & Tropical Medicine to provide a range of technology transfer services.
LifeArc negotiates exclusive licence deal with Nemysis Limited for oral iron supplement technology
LifeArc has negotiated a licence for an oral iron supplement technology with Nemysis Limited (Nemysis). Iron oxo-hydroxide adipate tartrate (IHAT) was developed at the Medical Research Council (MRC) Human Nutrition Research Unit, whose research LifeArc supports to increase the health benefits arising from MRC research.
LifeArc, Dstl and CDRD collaborate to identify antibacterial drug targets
LifeArc, The Centre for Drug Research and Development (CDRD), and the Defence Science and Technology Laboratory (Dstl) announced a collaboration to identify antibacterial drug targets.
LifeArc set to transform medical research landscape
Investing up to £500 million over the next five years to generate, fund and champion innovations in antimicrobials, neuroscience, personalised oncology and respiratory medicine.
MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer
Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform
Applying artificial intelligence in the search for new drugs
London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (MRCT)
Dementia Consortium funds Manchester based team targeting immune system in search for new dementia treatments
London, UK, 15 March 2017: The Dementia Consortium, a public-private partnership initiative bridging the gap between academic…